5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | NEUTRAL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.77▼ | 3.77▼ | 3.77▼ | 3.77▼ | 3.75▲ |
MA10 | 3.75▲ | 3.76▲ | 3.78▼ | 3.79▼ | 3.64▲ |
MA20 | 3.78▼ | 3.78▼ | 3.79▼ | 3.78▼ | 3.47▲ |
MA50 | 3.82▼ | 3.79▼ | 3.74▲ | 3.59▲ | 5.85▼ |
MA100 | 3.75▲ | 3.63▲ | 3.58▲ | 3.48▲ | 17.92▼ |
MA200 | 3.50▲ | 3.46▲ | 3.55▲ | 4.78▼ | 138.98▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | -0.003▼ | -0.006▼ | -0.020▼ | 0.306▲ |
RSI | 47.812▼ | 48.470▼ | 49.132▼ | 51.301▲ | 42.271▼ |
STOCH | 62.346 | 54.630 | 49.445 | 50.522 | 57.843 |
WILL %R | -53.333 | -53.333 | -53.333 | -48.010 | -41.287 |
CCI | -29.320 | -30.212 | -30.001 | -37.959 | 59.916 |
Wednesday, June 04, 2025 05:00 PM
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from ...
|
Monday, May 19, 2025 06:38 PM
On May 19, 2025, Qualigen Therapeutics, Inc. received a deficiency notification from Nasdaq due to its failure ... Spark’s Take on QLGN Stock According to Spark, TipRanks’ AI Analyst, QLGN ...
|
Monday, May 19, 2025 02:31 PM
See the full release here. Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 3.76 | 3.76 | 3.76 | 3.76 | 22 |
13/06/25 | 3.85 | 3.88 | 3.7001 | 3.712 | 6,381 |
12/06/25 | 3.76 | 4.00 | 3.70 | 3.822 | 5,188 |
11/06/25 | 3.678 | 3.798 | 3.6752 | 3.798 | 3,849 |
10/06/25 | 3.75 | 3.75 | 3.75 | 3.75 | 494 |
09/06/25 | 3.78 | 3.95 | 3.64 | 3.65 | 19,302 |
06/06/25 | 3.85 | 3.85 | 3.5001 | 3.75 | 3,664 |
05/06/25 | 3.98 | 3.98 | 3.75 | 3.81 | 2,605 |
04/06/25 | 3.855 | 3.9834 | 3.855 | 3.9834 | 4,007 |
03/06/25 | 3.85 | 3.8947 | 3.85 | 3.89 | 1,807 |
|
|
||||
|
|
||||
|
|